Your browser doesn't support javascript.
The impact of HMG-CoA reductase inhibitors use on the clinical outcomes in critically ill patients with COVID-19: A multicenter, cohort study.
Al Sulaiman, Khalid; Aljuhani, Ohoud; Korayem, Ghazwa B; Altebainawi, Ali F; Al Harbi, Shmeylan; Al Shaya, Abdulrahman; Badreldin, Hisham A; Kensara, Raed; Alharthi, Abdullah F; Alghamdi, Jahad; Alawad, Ahad; Alotaibi, Rand; Kharbosh, Abdullah; Al Muqati, Hessa; Alhuwahmel, Abdulmohsen; Almusallam, Mohammed; Albarrak, Ghada; Al Sulaihim, Ibrahim; Alanazi, Bader; Al-Dosari, Bodoor S; Vishwakarma, Ramesh; Alsaeedi, Alawi S; Al Ghamdi, Ghassan; Alkofide, Hadeel; Al-Dorzi, Hasan M.
  • Al Sulaiman K; Pharmaceutical Care Department, King Abdulaziz Medical City, Riyadh, Saudi Arabia.
  • Aljuhani O; College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
  • Korayem GB; King Abdullah International Medical Research Center-King Saud Bin Abdulaziz University for Health Sciences, Ministry of National Guard-Health Affairs, Riyadh, Saudi Arabia.
  • Altebainawi AF; Saudi Critical Care Pharmacy Research (SCAPE) Platform, Riyadh, Saudi Arabia.
  • Al Harbi S; Department of Pharmacy Practice, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia.
  • Al Shaya A; Department of Pharmacy Practice, College of Pharmacy, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia.
  • Badreldin HA; Pharmaceutical Care Services, King Salman Specialist Hospital, Hail Health Cluster, Hail, Saudi Arabia.
  • Kensara R; Pharmaceutical Care Department, King Abdulaziz Medical City, Riyadh, Saudi Arabia.
  • Alharthi AF; College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
  • Alghamdi J; King Abdullah International Medical Research Center-King Saud Bin Abdulaziz University for Health Sciences, Ministry of National Guard-Health Affairs, Riyadh, Saudi Arabia.
  • Alawad A; Pharmaceutical Care Department, King Abdulaziz Medical City, Riyadh, Saudi Arabia.
  • Alotaibi R; College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
  • Kharbosh A; King Abdullah International Medical Research Center-King Saud Bin Abdulaziz University for Health Sciences, Ministry of National Guard-Health Affairs, Riyadh, Saudi Arabia.
  • Al Muqati H; Pharmaceutical Care Department, King Abdulaziz Medical City, Riyadh, Saudi Arabia.
  • Alhuwahmel A; College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
  • Almusallam M; King Abdullah International Medical Research Center-King Saud Bin Abdulaziz University for Health Sciences, Ministry of National Guard-Health Affairs, Riyadh, Saudi Arabia.
  • Albarrak G; Pharmaceutical Care Department, King Abdulaziz Medical City, Riyadh, Saudi Arabia.
  • Al Sulaihim I; King Abdullah International Medical Research Center-King Saud Bin Abdulaziz University for Health Sciences, Ministry of National Guard-Health Affairs, Riyadh, Saudi Arabia.
  • Alanazi B; Pharmaceutical Care Department, King Abdulaziz Medical City, Riyadh, Saudi Arabia.
  • Al-Dosari BS; King Abdullah International Medical Research Center-King Saud Bin Abdulaziz University for Health Sciences, Ministry of National Guard-Health Affairs, Riyadh, Saudi Arabia.
  • Vishwakarma R; King Abdullah International Medical Research Center-King Saud Bin Abdulaziz University for Health Sciences, Ministry of National Guard-Health Affairs, Riyadh, Saudi Arabia.
  • Alsaeedi AS; Department of Pharmacy Practice, College of Pharmacy, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia.
  • Al Ghamdi G; Department of Pharmacy Practice, College of Pharmacy, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia.
  • Alkofide H; Clinical Pharmacy Department, Pharmacy College, Taif University, Taif, Saudi Arabia.
  • Al-Dorzi HM; Pharmaceutical Care Department, King Abdulaziz Medical City, Riyadh, Saudi Arabia.
Front Public Health ; 10: 877944, 2022.
Article in English | MEDLINE | ID: covidwho-2022931
ABSTRACT

Background:

The cardiovascular complications of Coronavirus Disease 2019 (COVID-19) may be attributed to the hyperinflammatory state leading to increased mortality in patients with COVID-19. HMG-CoA Reductase Inhibitors (statins) are known to have pleiotropic and anti-inflammatory effects and may have antiviral activity along with their cholesterol-lowering activity. Thus, statin therapy is potentially a potent adjuvant therapy in COVID-19 infection. This study investigated the impact of statin use on the clinical outcome of critically ill patients with COVID-19.

Methods:

A multicenter, retrospective cohort study of all adult critically ill patients with confirmed COVID-19 who were admitted to Intensive Care Units (ICUs) between March 1, 2020, and March 31, 2021. Eligible patients were classified into two groups based on the statin use during ICU stay and were matched with a propensity score based on patient's age and admission APACHE II and SOFA scores. The primary endpoint was in-hospital mortality, while 30 day mortality, ventilator-free days (VFDs) at 30 days, and ICU complications were secondary endpoints.

Results:

A total of 1,049 patients were eligible; 502 patients were included after propensity score matching (11 ratio). The in-hospital mortality [hazard ratio 0.69 (95% CI 0.54, 0.89), P = 0.004] and 30-day mortality [hazard ratio 0.75 (95% CI 0.58, 0.98), P = 0.03] were significantly lower in patients who received statin therapy on multivariable cox proportional hazards regression analysis. Moreover, patients who received statin therapy had lower odds of hospital-acquired pneumonia [OR 0.48 (95% CI 0.32, 0.69), P < 0.001], lower levels of inflammatory markers on follow-up, and no increased risk of liver injury.

Conclusion:

The use of statin therapy during ICU stay in critically ill patients with COVID-19 may have a beneficial role and survival benefit with a good safety profile.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Hydroxymethylglutaryl-CoA Reductase Inhibitors / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Adult / Humans Language: English Journal: Front Public Health Year: 2022 Document Type: Article Affiliation country: Fpubh.2022.877944

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Hydroxymethylglutaryl-CoA Reductase Inhibitors / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Adult / Humans Language: English Journal: Front Public Health Year: 2022 Document Type: Article Affiliation country: Fpubh.2022.877944